ADC Therapeutics Restructures: $86.6M PIPE, $70M Debt Paydown, HCR Royalty Rework
ADCT has more than doubled off its 52-week low of $0.78.
Summary
ADC Therapeutics announced a $86.6M PIPE, $70M debt paydown, and HCR royalty agreement amendments that extend cash runway into 2029 but add ~61M shares of potential dilution.
Key Events · Financing and Capital Events · ADCT
-
$86.6M PIPE at Deep Discount
12.9M common shares at $1.42 plus pre-funded warrants for 48.1M shares at $1.324, raising $86.6M gross. Pricing is well below the $1.82 share price at the time of this report.
-
Massive Potential Dilution
Combined 61M new shares (12.9M common + 48.1M warrant shares) represent roughly 2.6x the current ~23.5M share count implied by the $237.5M market cap at $1.82.
-
Debt Restructured to $50M Bullet
$70M term-loan prepayment reduces principal to $50M, eliminates minimum liquidity covenant, and defers all amortization to August 2029 maturity.
-
HCR Change-of-Control Payment Eliminated
The $150M payment triggered by a change of control is removed, replaced by a buyout option of $525M (before 2030) or $750M (after 2030), less royalties already paid.
Analysis · ADCT · Life Sciences
A comprehensive balance-sheet overhaul materially changes ADC Therapeutics' capital structure and survival runway. The $86.6M PIPE at $1.42 per share — a deep discount to the $1.82 price at the time of this report — combined with a $70M term-loan prepayment and elimination of the minimum liquidity covenant removes near-term covenant pressure. The HCR amendment eliminates a $150M change-of-control payment that would have made any acquisition prohibitively expensive, and reprices 9.8M HCR warrants from $3.81 to $0.10, creating significant future dilution. The company now projects cash runway into 2029, up from prior concerns, but the cost is substantial: roughly 61M new shares (12.9M common + 48.1M pre-funded warrants) against a market cap of only ~$237M. This is a survival financing that keeps the company alive to reach LOTIS-7 and MZL data readouts in December, but existing shareholders absorb heavy dilution.
How filings like this one have moved
In the 30 days to Nov 12, 2026, 49.5% of the 210 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.54%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ADCT was trading at $1.82 on NYSE in the Life Sciences sector, with a market capitalization of approximately $237.5M. The 52-week trading range was $0.78 to $4.98. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.